AJMC April 14, 2022
The Institute for Clinical and Economic Review (ICER) and researchers at NORC at the University of Chicago released a white paper that looks at the future of affordability and sustainability of drug development for rare disease through the lens of 4 policy proposals.
A white paper released this month examines 4 policy proposals that aim to address innovation and affordability in the realm of orphan drug development for rare diseases, including pricing and coverage.
The report was released by the Institute for Clinical and Economic Review (ICER) in collaboration with researchers at NORC at the University of Chicago.
“The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability” does not advocate for any specific solution, ICER said....
Today's Sponsors
Today's Sponsor